Development

Editor of Pharmaceutical Technology Europe

Articles

Dosage forms are being shaped by numerous factors, with patient-centricity continuing to be an important driver of decisions in development.

Driving Dosage Form Developments

Videos

In this episode of Drug Digest, Pharmaceutical Technology’s European/Senior Editor, Felicity Thomas, discusses small-molecule APIs, excipients, and formulation advances, including a discussion about novel approaches and solutions to pediatric formulations and taste-masking, a rundown of the fundamental stages of gaining a certificate of suitability for APIs, and a deliberation on the biggest trends impacting the industry and key sessions to visit while at CPHI, with several key industry experts. 

Drug Digest: A Big Impact: Trends Shaping Small-Molecule APIs, Excipients, and Formulations

Susan Haigney is managing editor of BioPharm International, susan.haigney@ubm.com.

Excipients should be treated equally when it comes to quality management, risk assessment, and testing.

In Equal Measures: The Importance of Excipient Quality

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Coprocessed excipients save time and cost while improving performance in a widening array of dosage forms.

Formulating with Coprocessed Excipients: Current Trends

The biggest hurdle is developing palatable formulations that are efficacious and patient friendly. 


Overcoming Challenges to Formulation Development for Pediatric Medicines

Podcasts

In this episode, David Tisi and Reenal Gandhi provide expert insights into advances and innovations changing the drug dosage form landscape.

Drug Solutions Podcast: Innovations and Advances in Drug Dosage Forms

Sample dilution, sensitivity, excipient interference, and containment are key issues that must be addressed.

Overcoming Analytical Challenges in High Potency Formulation

Nanotech-based delivery technologies are receiving significant attention.

Overcoming the Poor Solubility of Cannabinoids

This deal would help the companies merge to work on future projects and conduct research together.

SeraNovo and AstraZeneca Collaborate on Future Research Projects

Chris Spivey is the editorial director of 

Vibha Jawa, executive director at Bristol Myers Squibb, discusses foreign epitopes recognition from what should be fully human antibody therapies.